دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Markers of Myocardial Damage Predict Mortality in Patients With Aortic Stenosis
SoonguKwakMDaRussell J.EverettMD, PhDbThomas A.TreibelMD, PhDcSeokhunYangMDaDoyeonHwangMDaTaehoonKoPhDdMichelle C.WilliamsMD, PhDbRongBingMDbTrishaSinghBMbShrutiJoshiMBBSbHeesunLeeMDaWhalLeeMD, PhDeYong-JinKimMD, PhDaCalvin W.L.ChinMD, PhDfMihoFukuiMD, PhDgTariqueAl MusaMDhMarziaRigolliMDiAnveshaSinghMBChB, PhDjLionelTastetMSckLaura E.DobsonMDhStephanieWiesemannMDlVanessa M.FerreiraMD, DPhiliGabriellaCapturMD, PhDmSahminLeeMD, PhDnJeanetteSchulz-MengerMDlErik B.SchelbertMDoMarie-AnnickClavelDVM, PhDkSung-JiParkMD, PhDpTobiasRheudeMDqMartinHadamitzkyMDrBernhard L.GerberMD, PhDsDavid E.NewbyMD, PhDbSaul G.MyersonMDiPhillipePibarotDVM, PhDkJo?o L.CavalcanteMDoGerry P.McCannMBChB, MDjJohn P.GreenwoodMD, PhDhJames C.MoonMDcMarc R.DweckMD, PhDb?Seung-PyoLeeMD, PhDat?
doi : 10.1016/j.jacc.2021.05.047
Volume 78, Issue 6, 10 August 2021, Pages 545-558
Cardiovascular magnetic resonance (CMR) is increasingly used for risk stratification in aortic stenosis (AS). However, the relative prognostic power of CMR markers and their respective thresholds remains undefined.
Myocardial Damage and Severe Aortic Stenosis: Looking Beyond the Left Ventricular Ejection Fraction?
Cr?ch?n J.O’SullivanMD, PhD
doi : 10.1016/j.jacc.2021.05.046
Volume 78, Issue 6, 10 August 2021, Pages 559-561
Determinants and Outcomes of Asymptomatic Intracranial Atherosclerotic Stenosis
JoseGutierrezMD, MPHaFaridKhasiyevMDbMinghuaLiuPhDaJanet T.DeRosaMPHaSarah E.TomPhDacTatjanaRundekMD, PhDdefKenCheungPhDgClinton B.WrightMD, MShRalph L.SaccoMD, MSdefMitchell S.V.ElkindMD, MSac
doi : 10.1016/j.jacc.2021.05.041
Volume 78, Issue 6, 10 August 2021, Pages 562-571
Intracranial atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide and confers a high risk of stroke recurrence, despite aggressive management of risk factors.
Asymptomatic Intracranial Atherosclerotic Stenosis: The Risk Above the Carotids?
Tanya N.TuranMD, MSCRaKimberly P.KicielinskiMD, MSPHb
doi : 10.1016/j.jacc.2021.05.042
Volume 78, Issue 6, 10 August 2021, Pages 572-574
Multicenter Study of Endocarditis After Transcatheter Pulmonary Valve Replacement
Doff B.McElhinneyMDaYulinZhangPhDaJamil A.AboulhosnMDbBrian H.MorrayMDcEl?bieta KatarzynaBiernackaMD, PhDdAthar M.QureshiMDeAlejandro J.TorresMDfShabanaShahanavazMDgBryan H.GoldsteinMDhAllison K.CabalkaMDiHollyBauser-HeatonMD, PhDjStanimirGeorgievMDkFelixBergerMDlOscarMillan-IturbeMDmnLynn F.PengMDaAimee K.ArmstrongMDoDaniel S.LeviMDpAnetaFronczak-JakubczykMDdLarsSondergaardMDqJason H.AndersonMDiDietmarSchranzMD, PhDrThomas K.JonesMDcJohn P.CheathamMDnStephanSchubertMDls?PeterEwertMDk?
doi : 10.1016/j.jacc.2021.05.044
Volume 78, Issue 6, 10 August 2021, Pages 575-589
Endocarditis has emerged as one of the most impactful adverse events after transcatheter pulmonary valve replacement (TPVR), but there is limited information about risk factors for and outcomes of this complication.
Infective Endocarditis Complicating Transcatheter Pulmonary Valve Replacement: More Data, More to Learn?
Larry M.BaddourMDaThomas J.CahillMB BS, DPhilbBernard D.PrendergastBM, BS, DMc
doi : 10.1016/j.jacc.2021.05.043
Volume 78, Issue 6, 10 August 2021, Pages 590-593
Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death
Kathryn E.TobertBAaJ. MartijnBosMD, PhDabcRaminGarmanyBSadMichael J.AckermanMD, PhDabc
doi : 10.1016/j.jacc.2021.04.026
Volume 78, Issue 6, 10 August 2021, Pages 594-604
Within the last 5 years, cardiac society guidelines have begun to acknowledge shared decision making (SDM) for the athlete with sudden cardiac death–predisposing genetic heart diseases (GHDs), such as long QT syndrome (LQTS), and the possibility for that athlete’s return to play. Previously, international guidelines embraced a de facto disqualification for all such athletes including athletes with solely a positive genetic test in Europe.
Toward a Long and Happy Life of a Patient With Genetic Heart Disease?
Susan P.EtheridgeMDaElizabeth V.SaarelMDbc
doi : 10.1016/j.jacc.2021.04.047
Volume 78, Issue 6, 10 August 2021, Pages 605-607
Sleep Disordered Breathing and Cardiovascular Disease: JACC State-of-the-Art Review
Martin R.CowieMD, MScaDominikLinzMD, PhDbSusanRedlineMD, MPHcVirend K.SomersMD, PhDdAnita K.SimondsMDe
doi : 10.1016/j.jacc.2021.05.048
Volume 78, Issue 6, 10 August 2021, Pages 608-624
Sleep disordered breathing causes repetitive episodes of nocturnal hypoxemia, sympathetic nervous activation, and cortical arousal, often associated with excessive daytime sleepiness. Sleep disordered breathing is common in people with, or at risk of, cardiovascular (CV) disease including those who are obese or have hypertension, coronary disease, heart failure, or atrial fibrillation. Current therapy of obstructive sleep apnea includes weight loss (if obese), exercise, and positive airway pressure (PAP) therapy. This improves daytime sleepiness. Obstructive sleep apnea is associated with increased CV risk, but treatment with PAP in randomized trials has not been shown to improve CV outcome. Central sleep apnea (CSA) is not usually associated with daytime sleepiness in heart failure or atrial fibrillation and is a marker of increased CV risk, but PAP has been shown to be harmful in 1 randomized trial. The benefits of better phenotyping, targeting of higher-risk patients, and a more personalized approach to therapy are being explored in ongoing trials.
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the Week
CharlesHsuMDaEdwardHuttMB BSbDaniel M.BloomfieldMDcDavidGailaniMDdJeffrey I.WeitzMDef
doi : 10.1016/j.jacc.2021.06.010
Volume 78, Issue 6, 10 August 2021, Pages 625-631
Hemostasis and thrombosis are believed to be so intricately linked that any strategies that reduce thrombosis will have an inevitable impact on hemostasis. Consequently, bleeding is viewed as an unavoidable side effect of anticoagulant therapy. Emerging evidence suggests that factor XI is important for thrombosis but has a minor role in hemostasis. This information raises the possibility that anticoagulants that target factor XI will be safer than currently available agents. The authors provide a visual representation of the coagulation pathways that distinguishes between the steps involved in thrombosis and hemostasis to explain why factor XI inhibitors may serve as hemostasis-sparing anticoagulants. A safer class of anticoagulants would provide opportunities for treatment of a wider range of patients, including those at high risk for bleeding. Ongoing clinical studies will determine the extent to which factor XI inhibitors attenuate thrombosis without disruption of hemostasis.
Neighborhood Resources and Racial/Ethnic Differences in Survival After Myocardial Infarction
Jesse J.GoitiaJr.MDDerek Q.PhanMDFranzSchweisMDMaeregWassieMDYuh-JerAlbert ShenMD, MSBryanLinMSMing-SumLeeMD, PhD
doi : 10.1016/j.jacc.2021.06.007
Volume 78, Issue 6, 10 August 2021, Pages 632-633
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48
David D.BergMD, MPHRobert P.GiuglianoMD, SMChristian T.RuffMD, MPHMinaoTangMSKyungAhImPhDPetrJarolimMD, PhDHowardRutmanMD, MBAElliott M.AntmanMDEugeneBraunwaldMDDavid A.MorrowMD, MPH
doi : 10.1016/j.jacc.2021.06.008
Volume 78, Issue 6, 10 August 2021, Pages 634-636
Clarification Regarding the Lack of Heart Failure Events in the ASSAIL-MI Trial
Marco GiuseppeDel BuonoMDBenjamin W.Van TassellPharmDAntonioAbbateMD, PhD
doi : 10.1016/j.jacc.2021.04.105
Volume 78, Issue 6, 10 August 2021, Page 637
Reply: Clarification Regarding the Lack of Heart Failure Events in the ASSAIL-MI Trial
KasparBrochMD, PhDAnne KristineAnstensrudMDSindreWoxholtMDGeir ?ysteinAndersenMD, PhDLarsGullestadMD, PhD
doi : 10.1016/j.jacc.2021.06.005
Volume 78, Issue 6, 10 August 2021, Pages 637-638
The Association Between Fluoroquinolone Use and the Outcome of Aortic Aneurysm or Dissection
Chao-HsienChenMDCheng-YiWangMDChih-ChengLaiMD
doi : 10.1016/j.jacc.2021.05.045
Volume 78, Issue 6, 10 August 2021, Pages 638-639
Reply: The Association Between Fluoroquinolone Use and the Outcome of Aortic Aneurysm or Dissection
Shao-WeiChenMD, PhDYi-HsinChanMDVictorChien-Chia WuMDPao-HsienChuMDAn-HsunChouMD, PhD
doi : 10.1016/j.jacc.2021.06.009
Volume 78, Issue 6, 10 August 2021, Pages 639-641
